appendix
form
part
origin
submiss
peer
review
post
suppli
author
supplement
metcalf
cje
farrar
j
cutt
ft
et
al
use
serolog
survey
gener
key
insight
chang
global
landscap
infecti
diseas
lancet
publish
onlin
april
http
dx
antigen
vari
pathogen
group
two
figur
see
main
text
infect
result
immun
strainserotyp
caus
infect
individu
remain
suscept
strain
whether
multipl
serotyp
cocircul
eg
dengu
invas
bacteri
diseas
ibd
pathogen
evolut
immun
escap
eg
influenza
although
crossprotect
also
featur
pathogen
smith
et
al
serotyp
ibd
pneumococcu
ibd
antibodi
respons
protect
colon
like
differ
protect
invas
diseas
two
process
like
gener
variabl
antibodi
respons
might
modifi
respons
vaccin
ota
et
al
complic
interpret
serolog
data
complex
interact
strain
make
difficult
interpret
serolog
term
past
exposur
futur
infect
may
still
inform
infect
spread
et
al
combin
complex
strain
interact
human
immunodynam
eg
immun
wane
result
chang
immunolog
landscap
populationand
individuallevel
lessler
igg
antibodi
measl
rubella
correl
protect
moss
scott
consequ
data
routin
serosurvey
might
provid
earli
warn
larg
measl
outbreak
recent
surpris
public
health
practition
sever
countri
strebel
et
al
develop
network
serolog
survey
sentinel
site
surveil
throughout
countri
region
could
help
address
issu
infect
suscept
welldefin
serolog
detect
immun
target
level
could
use
trigger
time
vaccin
campaign
therebi
reduc
suscept
campaign
come
late
incorpor
outbreak
respons
team
within
larger
framework
world
serum
bank
would
potenti
allow
outbreak
respons
target
better
risk
approach
would
requir
abil
obtain
specimen
repres
sampl
individu
obtain
serolog
result
quickli
act
result
time
way
pointofcar
assay
current
evalu
infect
could
make
practic
long
threshold
serolog
titer
identifi
suscept
pair
serolog
individu
test
requir
greater
invest
howev
suitabl
power
studi
could
consider
enhanc
evalu
incid
antigen
variabl
pathogen
influenza
plu
improv
evalu
vaccin
campaign
eg
measl
rubella
move
beyond
acut
immun
infect
serosurvey
may
practic
method
rapidli
determin
extent
spread
clinic
silent
slowli
progress
infecti
diseas
burk
et
al
earli
aid
epidem
analysi
store
sera
key
understand
histor
time
introduct
epidem
natur
histori
krogh
et
al
sinc
antibodi
like
igg
persist
life
individu
host
lifespan
tend
greatli
exceed
timescal
pathogen
dynam
shift
igg
provid
window
past
present
fluctuat
diseas
et
al
repeat
sampl
defin
popul
grenfel
anderson
longitudin
sampl
individu
enrol
cohort
studi
provid
especi
clear
histor
window
dynam
infect
complex
immunolog
profil
spatial
histor
perspect
offer
serolog
survey
exploit
improv
understand
impact
infect
lifetim
exposur
franci
lessler
et
al
detect
epidemiolog
evolutionari
impact
secular
chang
popul
demographi
popul
mix
would
also
greatli
facilit
systemat
serum
collect
strengthen
understand
serolog
respons
relationship
immun
pathogenesi
evolv
multistrain
infect
yield
insight
immun
function
garnier
graham
immun
pressur
drive
pathogen
evolut
grenfel
et
al
smith
et
al
caus
sever
diseas
eg
via
antibodi
depend
enhanc
dengu
insight
repercuss
develop
deploy
novel
potenti
broadspectrum
vaccin
yamshchikov
et
al
limit
number
larg
serum
repositori
alreadi
exist
select
popul
purpos
us
depart
defens
serum
repositori
current
hous
million
specimen
continu
grow
approxim
million
specimen
per
year
see
http
wwwafhscmildodsr
experi
exist
repositori
could
exploit
develop
world
serum
bank
govern
structur
around
world
serum
bank
clearli
major
endeavor
could
draw
experi
similar
bodi
eg
http
genomicsandhealthorgaboutglobalalli
ethic
legal
social
issu
consent
privaci
proper
use
specimen
may
pose
challeng
cadigan
et
al
mani
detail
remain
work
sustain
fund
storag
size
sampl
scheme
degre
noninvas
specimen
collect
oral
fluid
encompass
etc
principl
clear
past
sever
decad
seen
revolut
genom
analysi
infecti
diseas
contrast
mani
gold
standard
serolog
techniqu
unchang
decad
requir
expertis
avail
laboratori
timeconsum
expens
conduct
larg
number
sera
standard
method
lab
also
challeng
develop
broadspectrum
microarray
antibodi
spectrum
infecti
diseas
eg
sivakumar
et
al
activ
area
could
revolution
popul
serosurvey
allow
us
tackl
multiplex
rang
public
health
research
question
prohibit
expens
figur
organ
across
four
major
categori
infect
rel
serolog
plot
degre
serolog
assay
provid
reliabl
signatur
exposur
x
axi
signatur
protect
axi
rel
posit
schemat
move
left
right
mani
infect
titr
neutral
antibodi
rather
simpli
titr
antibodi
particular
specif
would
provid
signatur
protect
assay
select
would
need
tailor
accordingli
underlin
indic
pathogen
longlast
immun
transmiss
although
dengu
broadli
categor
belong
group
relationship
serolog
correl
protect
complic
antibodi
enhanc
